Ovarian cancer is a relatively manageable malignancy ... several groups have pioneered the task in determining HE4's efficacy as a molecular marker for OC. Although HE4 has consistently shown ...

Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

In the last few years, much attention has been paid to this novel tumor marker that can be determined ... malignancy as well as for lung cancer, breast cancer, ovarian cancer, renal cancer ...

The ChemoFx® treatment selection marker and tumor ... 250,000 gynecologic cancer cases are diagnosed each year, the most frequent of which are endometrial, cervical and ovarian. "Of the approximately ...